No profile data available.
Alto Neuroscience, Inc. (ANRO) is a healthcare company in the brain and nerve treatment drugs industry, based in Mountain View, United States, with about 68 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$63.24 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $956.33 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).
Alto Neuroscience reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$956.33 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include GH Research PLC (GHRS), LB Pharmaceuticals Inc (LBRX), Capricor Therapeutics, Inc. (CAPR), Annexon, Inc. (ANNX).